GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000616421 | Stomach | CSG | purine nucleotide biosynthetic process | 28/1034 | 191/18723 | 2.20e-06 | 9.85e-05 | 28 |
GO:000911721 | Stomach | CSG | nucleotide metabolic process | 52/1034 | 489/18723 | 4.59e-06 | 1.84e-04 | 52 |
GO:007252221 | Stomach | CSG | purine-containing compound biosynthetic process | 28/1034 | 200/18723 | 5.46e-06 | 2.08e-04 | 28 |
GO:000675321 | Stomach | CSG | nucleoside phosphate metabolic process | 52/1034 | 497/18723 | 7.29e-06 | 2.62e-04 | 52 |
GO:000663121 | Stomach | CSG | fatty acid metabolic process | 43/1034 | 390/18723 | 1.25e-05 | 4.20e-04 | 43 |
GO:000916521 | Stomach | CSG | nucleotide biosynthetic process | 31/1034 | 254/18723 | 2.93e-05 | 8.26e-04 | 31 |
GO:190129321 | Stomach | CSG | nucleoside phosphate biosynthetic process | 31/1034 | 256/18723 | 3.42e-05 | 9.31e-04 | 31 |
GO:00066332 | Stomach | CSG | fatty acid biosynthetic process | 19/1034 | 163/18723 | 1.68e-03 | 1.85e-02 | 19 |
GO:00463942 | Stomach | CSG | carboxylic acid biosynthetic process | 30/1034 | 314/18723 | 2.52e-03 | 2.46e-02 | 30 |
GO:00160532 | Stomach | CSG | organic acid biosynthetic process | 30/1034 | 316/18723 | 2.77e-03 | 2.63e-02 | 30 |
GO:0022411113 | Thyroid | PTC | cellular component disassembly | 232/5968 | 443/18723 | 1.36e-19 | 1.75e-17 | 232 |
GO:0016236110 | Thyroid | PTC | macroautophagy | 167/5968 | 291/18723 | 1.51e-19 | 1.91e-17 | 167 |
GO:0032984110 | Thyroid | PTC | protein-containing complex disassembly | 114/5968 | 224/18723 | 2.26e-09 | 6.33e-08 | 114 |
GO:001969327 | Thyroid | PTC | ribose phosphate metabolic process | 176/5968 | 396/18723 | 8.28e-08 | 1.70e-06 | 176 |
GO:000915028 | Thyroid | PTC | purine ribonucleotide metabolic process | 165/5968 | 368/18723 | 1.03e-07 | 2.05e-06 | 165 |
GO:007252127 | Thyroid | PTC | purine-containing compound metabolic process | 182/5968 | 416/18723 | 1.92e-07 | 3.51e-06 | 182 |
GO:000925927 | Thyroid | PTC | ribonucleotide metabolic process | 170/5968 | 385/18723 | 2.32e-07 | 4.08e-06 | 170 |
GO:000616327 | Thyroid | PTC | purine nucleotide metabolic process | 170/5968 | 396/18723 | 2.02e-06 | 2.75e-05 | 170 |
GO:000675325 | Thyroid | PTC | nucleoside phosphate metabolic process | 205/5968 | 497/18723 | 5.24e-06 | 6.35e-05 | 205 |
GO:000911725 | Thyroid | PTC | nucleotide metabolic process | 202/5968 | 489/18723 | 5.46e-06 | 6.60e-05 | 202 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TEC | SNV | Missense_Mutation | | c.1117A>T | p.Met373Leu | p.M373L | P42680 | protein_coding | tolerated(1) | benign(0.037) | TCGA-A8-A09K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TEC | SNV | Missense_Mutation | rs780984861 | c.1393N>A | p.Val465Ile | p.V465I | P42680 | protein_coding | tolerated(0.23) | benign(0.001) | TCGA-AO-A12A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TEC | SNV | Missense_Mutation | | c.1564T>G | p.Ser522Ala | p.S522A | P42680 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
TEC | SNV | Missense_Mutation | | c.1191C>G | p.Ile397Met | p.I397M | P42680 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TEC | SNV | Missense_Mutation | | c.700N>T | p.Val234Leu | p.V234L | P42680 | protein_coding | tolerated(0.4) | probably_damaging(0.997) | TCGA-C8-A278-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
TEC | SNV | Missense_Mutation | rs761984494 | c.806N>A | p.Gly269Asp | p.G269D | P42680 | protein_coding | deleterious(0) | benign(0.403) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
TEC | insertion | In_Frame_Ins | novel | c.587_588insAAATATAAAATTTAATTTCCCTCAAGGTCAAAATAATCACATTAAACA | p.Gly195_His196insGlnAsnIleLysPheAsnPheProGlnGlyGlnAsnAsnHisIleLys | p.G195_H196insQNIKFNFPQGQNNHIK | P42680 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TEC | deletion | Frame_Shift_Del | novel | c.1348delN | p.Leu450PhefsTer2 | p.L450Ffs*2 | P42680 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TEC | SNV | Missense_Mutation | rs750190240 | c.700N>A | p.Val234Ile | p.V234I | P42680 | protein_coding | tolerated(0.08) | probably_damaging(0.994) | TCGA-ZJ-AAXB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TEC | SNV | Missense_Mutation | rs539573453 | c.550N>A | p.Val184Ile | p.V184I | P42680 | protein_coding | deleterious(0.05) | benign(0.039) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |